Kornimate/medical-research-clean huggingface dataset:
study on the role of mitochondrial dysfunction in the pathogenesis of metformin-associated lactic acidosis

Conditions: Lactic Acidosis; Metformin

Summary: metformin is the first line drug of choice for the treatment of type ii diabetes. lactic acidosis can develop as a side effect, especially when renal failure leads to drug accumulation. lactic acidosis is usually attributed to an abnormal inhibition of hepatic lactate clearance. growing evidence suggest that metformin can dose-dependently inhibit hepatocyte mitochondrial function. whether a similar effect occurs in extra-hepatic human tissues remains unknown. the investigators hypothesize that mitochondrial dysfunction occurs during metformin intoxication even in tissues other than the liver, thus contributing to the development of lactic acidosis. the aim of this study is to investigate mitochondrial integrity in circulating platelets of patients with lactic acidosis due to metformin intoxication.


Eligibility criteria:
inclusion criteria: 1. lactic acidosis (ph \ 5 mmol/l and lactate \> 5 mmol/l) 2. metformin intoxication (serum drug level \> 4 mcg/ml) 3. absence of evidence of any other condition that could primarily explain the lactic acidosis exclusion criteria: 1. less than 18 years of age 2. hemoglobin \< 8 g/dl (10 g/dl if ischemic cardiac disease)
incidence and outcomes of acute kidney injury in postoperative icu patients - a retrospective data analysis

Conditions: Acute Kidney Injury; ICU; Postoperative Patients

Summary: acute kidney injury (aki) is a common complication in critically ill patients. based on the sensitive kdigo criteria, the incidence of aki on icu varies between 30-60 %. these large variations of incidence of aki are due to different baseline characteristics of studied patients, the length of observation period, use of creatinine criteria only or use of creatinine and urine output criteria. furthermore, back estimation of baseline creatinine instead of measured creatinine in patients with missing laboratory values may lead to overestimation of aki severity and outcomes. major surgery, trauma, infection, sepsis or a complication of severe illness can lead to an abrupt decrease in glomerular filtration in critically ill patients. such episode of aki is associated with short term adverse effects such as fluid overload, electrolyte imbalance, acid-base derangements, immune dysfunction, coagulation abnormalities and alterations in mental status. additionally, aki in critically ill patients leads to prolonged icu length of stay, increase in morbidity and mortality as well as higher costs. multiple large studies found, after correction for potential confounders, that aki was independently associated with worse outcomes. moderate and severe aki stages were associated with 2.9 - 6.9 fold increased in-hospital mortality (3). increasing aki severity in icu patients was not only associated with increased mortality, aki patients had also worse renal function at the time of hospital discharge. the individual condition leading to aki in combination with increased susceptibility to aki may significantly influence outcome. indeed, current data from many studies show that mortality from aki differs in various clinical settings. however, there are not enough data on different types of surgery and their effect on aki yet. the aim of our epidemiological study is to investigate the occurrence and outcomes of aki in different types of surgery in postoperative icu patients at the vienna general hospital.


Eligibility criteria:
inclusion criteria: * age \> 18 years * postoperative icu admission * preoperative serum creatinine within 2 weeks prior surgery exclusion criteria: * age \< 18 years * no surgery prior to icu admission * renal transplantation prior icu admission * chronic renal replacement therapy * peritoneal dialysis * missing preoperative serum creatinine within 2 weeks prior surgery

Keywords: aki kdigo icu postoperative
phase 3 clinical trial of wujia yizhi granules in the treatment of mild-to-moderate alzheimer's dementia (syndrome of deficiency of spleen and kidney)

Conditions: Alzheimer's Dementia

Summary: this study is a randomized, double-blind, placebo-controlled phase 3 design aimed at further verifying the safety and efficacy of wujia yizhi granules for mild-to-moderate alzheimer's dementia

this is a multi-center, randomized, double-blind, placebo-controlled phase 3 clinical trial targeting patients with mild-to-moderate alzheimer's dementia (tcm differentiated as syndrome of deficiency of spleen and kidney). 570 subjects were recruited and randomly assigned to the experimental and placebo groups at a ratio of 2:1.

Eligibility criteria:
inclusion criteria: 1. male or female, age range : 50 - 80 years old. 2. informed consent signed and dated by patient or legal representative. 3. the participants are mild-to-moderate ad patients who meet the diagnostic criteria for ad proposed by the national institute on aging and the alzheimer's association (nia-aa) in 2018 and have a disease course of more than 6 months. if participants lack previous pathological evidence or biomarkers of alzheimer's dementia, they must have evidence of β-amyloid deposition biomarkers during screening (pet with abnormal amyloid deposition or low cerebrospinal fluid aβ 42 and aβ 42/aβ 40 ratio). 4. mmse score 11 to 26;cdr-gs score 1 to 2 。 exclusion criteria: 1. participants with non ad induced memory and cognitive impairment, such as diagnosis of other types of dementia, including but not limited to mixed dementia (ad vad), vascular dementia (vd), parkinson's disease dementia (pdd), lewy body dementia (dlb), huntington's disease related dementia, frontotemporal lobe dementia (ftd), etc; endocrine system disorders (such as thyroid diseases, parathyroid diseases) and dementia caused by folate, vitamin b12 deficiency, or any other reason; existence of consciousness disorders, etc. 2. participants have a history of epileptic seizures. 3. participants are psychiatric patients, including but not limited to schizophrenia, affective schizophrenic disorder, bipolar disorder, or delirium. 4. hamd-17 score ≥ 17 points. 5. hama score ≥ 14 points. 6. participants were taking antidepressants, anxieties, and antipsychotic drugs during screening. 7. his score ≥ 4 points..
efficacy and safety of bi 2536 in advanced or metastatic non small cell lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: the trial will be performed to evaluate whether bi 2536 may be effective in the treatment of advanced or metastatic nsclc of stage iiib or iv in patients who relapsed after or failed first-line therapy. a secondary aim is to identify the most suitable dosage schedule for the further phase ii and iii clinical programme of bi 2536. to achieve this objective two dosage schedules are compared.


Eligibility criteria:
inclusion criteria: male or female patients aged 18 years or older with histologically or cytologically confirmed advanced or metastatic nsclc of stage iiib or iv, who relapsed or failed prior first-line chemotherapy for advanced or metastatic disease. at least one tumour lesion must be present that can accurately be measured by magnetic resonance imaging (mri), or computed tomography (ct) in at least one dimension (longest diameter to be recorded) as 20 mm or greater with conventional techniques or as 10 mm or greater with spiral ct scan. life expectancy of at least three months; eastern co-operative oncology group (ecog) performance score of 2 or less and written informed consent which must be consistent with international conference on harmonisation good clinical practice (ich-gcp) and local legislation exclusion criteria: persistence of toxicities of prior anti cancer therapies which are deemed to be clinically relevant, known secondary malignancy requiring therapy, brain metastases which are symptomatic or require therapy, absolute neutrophil count less than 1,500/mm3, platelet count less than 100,000/mm3, haemoglobin less than 9 mg/dl, aspartate amino transferase (ast) or alanine amino transferase (alt) greater than 2.5 times the upper limit of normal, or ast or alt greater than 5 times the upper limit of normal in case of known liver metastases, bilirubin greater than 1.5 mg/dl, serum creatinine greater than 2.0 mg/dl, concomitant intercurrent illnesses that would limit compliance with trial requirement or which are considered relevant for the evaluation of the efficacy or safety of the trial drug, chemo-, hormone- or immunotherapy within the past four weeks or within less than four half-life times of the previous drug prior to treatment with the trial drug (whatever is the longest period), radiotherapy within the past four weeks prior to treatment with the trial drug, men or women who are sexually active and unwilling to use a medically acceptable method of contraception during the trial, pregnancy or lactation, treatment with any other investigational drug within the past four weeks or within less than four half-life times of the investigational drug before treatment with the trial drug (whatever is the longest period), patient unable to comply with the protocol, patients who are considered eligible by the investigator for other second-line chemotherapy, radiotherapy or immunotherapy, patients who have received more than two lines of prior anti-tumour therapy for advanced or metastatic non small cell lung cancer
short and fast step test: feasibility, validity and tolerance of a functional evaluation test of lactic anaerobic capacities in patients with coronary artery disease

Conditions: Coronary Artery Disease Without Heart Failure

Summary: recommendations for cardiovascular rehabilitation (cvr) encourage exercise training, primarily involving the aerobic system, to allow patients to regain independence in daily activities. however, the lactic anaerobic process is also involved during these activities (stair climbing, carrying loads, etc.). hence there is a major interest in accurately assessing patients' anaerobic capacities in order to tailor suitable exercise programs. however, there are no functional tests specifically dedicated to the evaluation of lactic anaerobic metabolism and adapted to people with coronary disease. the investigators offer a dedicated test, the short and fast test (sfst), which can be applied in current clinical practice and has already been evaluated in a population of healthy subjects. the purpose of this project is to evaluate the safety, feasibility and validity of sfst in a population of patients with coronary artery disease.


Eligibility criteria:
inclusion criteria: - patient who has given oral consent adult patient (male or female) with coronary artery disease without heart failure referred for rehabilitation program left ventricular ejection fraction (simpson method) \> 45%. exclusion criteria: * protected adult * patient not affiliated to a national health insurance scheme * pregnant or breastfeeding woman * orthostatic hypotension * severe obstructive heart disease * aortic valve narrowing * progressive severe cardiac rhythm or conduction disorders not requiring a device, detected during the initial stress test. * intracavitary cardiac thrombus * severe pulmonary arterial hypertension (systolic pulmonary hypertension \>70mmhg) * recent venous thromboembolic history (last 3 months) * heart transplantation * associated medical condition that can predominantly impair functional and respiratory capacities (examples: unstabilized metabolic disorders such as progressive renal failure, significant asthenia related to a severe unstabilized condition such as neoplasia, systemic disease, chronic obstructive pulmonary disease...) * physical impairments of the lower limbs hindering the test, whether neurological (central or peripheral), arterial (in particular, arteriopathy of the lower limbs with systolic index \< 0.6) or orthopedic (degenerative or inflammatory rheumatism) * treatment with corticosteroids, anabolics, or l-carnitine.
study on the brain network of angelman syndrome

Conditions: Angelman Syndrome

Summary: the aims of study on angelman syndrome: 1. establish the angelman syndrome database 2. explore the brain network of angelman syndrome based on multi-modal brain image and neural-eeg data

1. the participants recruitment: from chinese angelman syndrome patients group (angelhome : angelman225@126.com) and children's hospital of fudan university. 2. fistly all participants had clinically and molecularly confirmed as angelman syndrome . all participants should entry the online questionnaries and carified by telephone or on site . all the information will be recorded in the angelman syndrome database. investigators will analyze and summarize the relationship of phenotype and genotype(n=200). 3. participants who assigned the informed consent and will undergo the brain mri inspection and neural-eeg recording in the children's hospital of fudan university. the healthy age- and sex-matched control participants will enrolled in the same hospital. the investigators will explore the brain morphology and electrophysiological alterations and for angelman syndrome (as) children among the different genotypes（n=200）.

Eligibility criteria:
inclusion criteria: * clinical and molecular diagnosis of angelman syndrome. * agreed and completed the mri scan and eeg-recording by using oral chloral hydrate. exclusion criteria: * reject mri scan and eeg-recording by using oral chloral hydrate or unable to complete the scan.

Keywords: as database mri eeg
reversing diabetic peripheral neuropathy through exercise

Conditions: Peripheral Neuropathy; Diabetes

Summary: this project proposes a longitudinal design that uses multinuclear-mri to evaluate the mechanistic effects of exercise on skeletal muscle function and peripheral nerve integrity in patients with diabetic peripheral neuropathy (dpn), and to determine whether exercise can reverse dpn symptoms. the investigators will prescribe a 10-week exercise program to 40 dpn patients. the investigators will acquire multinuclear-mri data before and after the intervention that can provide mechanistic insight into the adaptations in lower leg muscle function and peripheral nerve integrity of patients with dpn, and their role in improving dpn symptoms following physical exercise intervention.


Eligibility criteria:
inclusion criteria: * be between the ages of 40 and 70 * clinical diagnosis of type 2 diabetes * clinical diagnosis of dpn * have a bmi less than 40 kg/m2 (due to magnet bore restrictions) * able to walk unassisted exclusion criteria: * serious cardiac pathology or musculoskeletal problems that would limit exercise ability * mnsi score \< 1 * current open wound or history of plantar ulcer for the last 3 months * partial foot amputations * inability to ambulate without assistive device * stroke or other central nervous system pathology * stage 2 hypertension (resting blood pressure \>160 systolic or \>100 diastolic) * contraindications to 3t whole body mri scanners (e.g., pacemaker, cerebral aneurysm clip, cochlear implant, presence of shrapnel in strategic locations, metal in the eye, claustrophobia, or other problems). * subjects with alcoholism, chronic drug use, chronic gastrointestinal disease, or renal or hepatic impairment * pregnant women and children

Keywords: exercise
evaluation of the effectiveness of extracorporeal methods for removing mediators of systemic inflammation

Conditions: Renal Failure Acute; Multiple Organ Failure; Cardiovascular Diseases

Summary: the purpose of this study is to assess the effectiveness and the safety of extracorporeal methods for removing mediators of systemic inflammation in patients with multiple organ dysfunction syndrome after heart and aorta surgery.

after being informed about the study and potential risk, all patients with multiple organ dysfunction syndrome after heart and aorta surgery with indications for extracorporeal removal of inflammatory mediators, giving written informed consent will be included in the study. patients will be randomized 1:1 ratio to 1. hemoperfusion cartridge for cytokine sorption in combination with an oxiris membrane and 2. oxiris membrane.

Eligibility criteria:
inclusion criteria: * multiple organ dysfunction; * sofa equal to or more than 4; * crp equal to or more than 100 ng / ml; * increase of il6 by 5 times or more exclusion criteria: * the impossibility to use heparin ( bleeding; heparin-induced thrombocytopenia)

Keywords: mediators of systemic inflammation extracorporeal methods interleukins
functional outcomes following ankle fracture fixation with or without ankle arthroscopy

Conditions: Ankle Fractures; Ankle Injuries; Arthroscopic Surgery

Summary: the aim of our study is to identify if there is statistically significant difference in patient reported functional outcomes in cases of unstable ankle fracture managed by orif with and without ankle arthroscopy.

acute ankle fracture is one of the commonest fractures of the lower limb. anatomical reduction and stable fixation remain the main surgical treatment for unstable ankle fractures . however, its final outcomes are not as good as expected . fracture malunion, failure to address the disrupted syndesmosis and associated ligamentous or chondral lesions can be reasons for poor surgical outcome. 1-mm of lateral talar shift lead to a 42% increase in contact stress, so the anatomic reduction is critical to the long-term integrity of the joint . it is difficult to assess 1 to 2 mm of mal-reduction with c-arm fluoroscopy. the best assessment of the syndesmotic reduction is performed with axial ct imaging of the ankle. ankle arthroscopy is expected to be a more sensitive tool for syndesmotic disruption diagnosis and other intra-articular pathologies and as a guide for anatomical reduction of the syndesmosis . several studies have reported the incidence of chondral lesions seen during ankle arthroscopy at the time of ankle fracture orif, but those studies report the role of arthroscopy as a diagnostic or predictive tool for patient outcome. very few studies have discussed the rates of arthroscopic intervention, the procedures performed, and the association of these procedures with patient final functional outcomes .

Eligibility criteria:
inclusion criteria: * patients ≥16 years of age who will be managed operatively for: * rotational ankle fracture danis-weber classification b or c fibula fracture * fracture dislocation ankle * fractures extending into the tibial plafond, * talus fractures (body or neck) in our institution exclusion criteria: pediatric fractures, polytrauma patients, fractures managed with closed-contact casting and, patients with lost follow up during this study

Keywords: functional outcomes of ankle fracture management ankle scope syndesmosis reduction ankle ligaments evaluation
a study using tacrolimus, sirolimus and bortezomib as acute graft versus host disease (gvhd) prophylaxis in allogeneic peripheral blood stem cell (pbsc) transplantation

Conditions: Graft vs Host Disease; Peripheral Blood Stem Cell Transplantation; Transplantation, Homologous

Summary: the purpose of this study is determine the highest dose of bortezomib, a new drug for graft-versus host disease prevention, that can be given in combination with sirolimus and tacrolimus, without causing severe side effects. this research is being done because there is no treatment that is 100% effective in preventing graft versus host disease. the goals of this study are to: 1. collect peripheral blood stem cells (pbscs) from donors for transplant. 2. determine the largest possible dose of bortezomib that can be given to recipients with various blood cancers in a safe manner. 3. monitor the recipient for risk of infection or side affects associated with the transplant. 4. monitor the recipient for increased immunity following transplantation.


Eligibility criteria:
inclusion criteria: * undergoing myeloablative peripheral blood stem cell transplantation * have an hla matched-related or matched-unrelated donor (9/10 antigen or allelic mismatch or 10/10 hla match permitted). * hematological malignancy including patients with: aml, all, nhl, hodgkin's disease, cll, cml, mds and multiple myeloma * meeting institutional standard criteria for allogeneic pbsc transplantation exclusion criteria: * patient has \>grade 2 peripheral neuropathy within 14 days before enrollment. * history of autologous or allogeneic transplantation * evidence of hiv seropositivity * evidence of active infection * patients with cardiac dysfunction as described in the protocol * patients with hypersensitivity to bortezomib, boron or mannitol

Keywords: tacrolimus sirolimus bortezomib acute graft versus host disease allogeneic peripheral blood stem cell transplantation
efficacy and safety of azithromycin sr compared with minocycline in acne

Conditions: Acne Vulgaris

Summary: the primary objective is to evaluate the clinical efficacy of azithromycin microspheres treatment in outpatients with moderate to severe inflammatory acne compared with first line treatment minocycline after 8 weeks of therapy

the study prematurely discontinued on the february 1, 2008 due to slow enrollment.it should be noted that safety concerns have not been seen in this study and have not factored into this decision.

Eligibility criteria:
inclusion criteria: * male and female, \> 16 years of age, with diagnosis of acne papulo-pustular, moderate (19-30 gags score) to severe (31-33 gags score) exclusion criteria: * pregnancy, gastrointestinal and endocrinological disease, specific systemic disease, hormonal contraceptives, isotretinoin, topic drugs for acne (except detergent allowed)
efficacy of transcutaneous electrical nerve stimulation (tens) for pain reduction during intrauterine device (iud) insertion in outpatient gynecology

Conditions: IUD Insertion Pain

Summary: pain with intrauterine device (iud) insertion is very common and there are few options for patients to help reduce this pain. transcutaneous electric nerve stimulators (tens) are a non-invasive procedure that may help reduce the pain with iud insertions. the investigators hope that the information gleaned from this study will result in pain control options for future patients who desire an iud placement.


Eligibility criteria:
inclusion criteria: * age 18-45 years old * individuals with a cervix and uterus * seeking intrauterine device (iud) placement for contraception or management of abnormal uterine bleeding * meet medical eligibility for iud placement * ability to consent in english * ability to use the visual analogue scale (vas) exclusion criteria: * contraindications to iud placement * use of analgesics within the last 4 hours prior to iud placement * presence of a pacemaker

Keywords: contraception